Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI9314 in healthy adults
NCT02669667Phase 1Completed
- Sponsor
- MedImmune
- Start
- Feb 2016
- Primary completion
- Nov 2016
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of MEDI9314 in atopic dermatitis (AD) (6 cohorts), sponsored by MedImmune. Primary endpoints: Treatment-emergent Adverse Events at Day 240, Electrocardiogram Abnormalities Reported as TEAEs at Day 240 and 4 more. Started Feb 2016; status: completed.
02
Drugs
MEDI9314
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT02669667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02669667.